Published by Frank Prenesti on 26th October 2022
(Sharecast News) - AstraZeneca said its capivasertib breast cancer drug combined with Faslodex hormone treatment demonstrated a "statistically significant and clinically meaningful improvement" in progression-free patient (PFS) survival during a late-stage trial.
URL: http://www.digitallook.com/dl/news/story/33061352/...